Venture Life Group PLC announced its unaudited interim results for the 12-month period ended 31 December 2025, highlighting a strategic shift to a pure-play consumer healthcare company. Key points include
**Revenue Growth**Group revenue increased by 32.2% to £35.2 million, with a 11.4% proforma growth, driven by strong performance in the UK and the acquisition of Health & Her Limited.
**Divestments**Sold CDMO operations and non-core products for €62 million and oral care brands for up to £4.5 million, simplifying the business model and generating significant cash.
**Profitability**Adjusted EBITDA decreased by 3.6% to £6.0 million due to temporary cost base adjustments post-divestments, while adjusted profit before tax increased to £4.9 million.
**Cash Position**Received £56.1 million from divestments, repaid the RCF, and ended with £34.2 million in cash, positioning the company for M&A activities.
**Strategic Focus**Transitioned to a capital-light, brand-focused, omnichannel approach, with reinvestment in senior management and digital capabilities.
**Operational Highlights**Successfully integrated Health & Her, launched new products, and strengthened leadership.
**Post-Period Performance**Q1 revenues trading 18% ahead of prior year, with gross margin improvement and continued M&A progress.
**Shareholder Returns**Returned £4.7 million to shareholders via a share buyback program, acquiring 7.0 million shares.
**Future Outlook**Confident in meeting guidance for the 17-month period ending 31 May 2026, with a focus on organic and acquisitive growth.
| Metric | 2024 | 2025 | Change |
|---|---|---|---|
| Revenue (£ million) | 26.6 | 35.2 | +32.3% |
| Gross Profit (£ million) | 12.2 | 15.8 | +30.0% |
| Adjusted EBITDA (£ million) | 6.2 | 6.0 | -3.6% |
| Operating (Loss)/Profit (£ million) | 1.5 | (1.3) | N/A |
| Net Debt (£ million) | 20.1 | (33.5) | N/A |
| Cash Position (£ million) | 3.1 | 34.2 | +1003.2% |
| Free Cash Flow (£ million) | 3.7 | 3.3 | -10.8% |
Notes:
- The company transitioned from net debt to a cash position due to the receipt of £56.1 million in cash proceeds from divestments and the repayment of the RCF.
- The operating loss in 2025 is primarily due to exceptional costs and the temporary disproportionate position of the operating cost base after divestments.